ସାଇପ୍ରୋହେପ୍ଟାଡାଇନ

ସାଇପ୍ରୋହେପ୍ଟାଡାଇନ
Clinical data
Pronunciation	(/ˌsaɪproʊˈhɛptədiːn/
Trade names	Periactin, others
AHFS/Drugs.com	monograph
MedlinePlus	a682541
data	US DailyMed: Cyproheptadine;
Pregnancy; category	AU: A ; US: B (No risk in non-human studies) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S3 (Pharmacist only) ; CA: OTC ; UK: General sales list (GSL, OTC) ; US: ℞-only ; OTC;
Pharmacokinetic data
Protein binding	96 to 99%
Metabolism	Liver Mostly CYP3A4 mediated.
Elimination half-life	8.6 hours
Excretion	Faecal (2-20%; 34% of this as unchanged drug) and renal (40%; none as unchanged drug)
Identifiers
	IUPAC name 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine;
ECHA InfoCard	100.004.482
Chemical and physical data
Formula	C21H21N
Molar mass	୨୮୭.୪୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4;
	InChI InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3 ; Key:JJCFRYNCJDLXIK-UHFFFAOYSA-N ;
(verify)

ସାଇପ୍ରୋହେପ୍ଟାଡାଇନ, ଏକ ବ୍ୟବସାୟୀକ ନାମ ପେରିଆକ୍ଟିନ୍, ହେଉଛି ପ୍ରଥମ ପିଢ଼ୀର ଆଣ୍ଟିହିଷ୍ଟାମିନ ଯାହା ମୁଖ୍ୟତଃ ଆଲର୍ଜି ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୫] ^[୬] ଏଥିରେ ଗଲୁ, ଆଲର୍ଜିକ ନାକ ପ୍ରଦାହ ଏବଂ ହାଇଭ୍‌ସ ଅନ୍ତର୍ଭୁକ୍ତ କରାଯାଏ ।^[୭] ଏହା ପାଟିରେ ନିଆଯାଏ । ^[୮]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିଦ୍ରାଳୁ ଭାବ, ମୁଣ୍ଡ ବୁଲାଇବା, ଉତ୍ତେଜନା ଏବଂ ସମନ୍ୱୟ ଅଭାବ ଦେଖାଯାଏ । ^[୫] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଫୁଲା, ପରିସ୍ରା ଜନିତ ସମସ୍ୟା ଏବଂ ଓଜନ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୬] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ସହିତ କୌଣସି କ୍ଷତି ହେବାର ପ୍ରମାଣ ନାହିଁ, କିନ୍ତୁ ଏହିପରି ବ୍ୟବହାର ଭଲ ଭାବରେ ଅଧ୍ୟୟନ କରାଯାଇ ନାହିଁ | ^[୯] ଗ୍ଲକୋମା ସଙ୍କଟ ଥିବା ଲୋକ ପ୍ରତି ଯତ୍ନବାନ ହେବା ଉଚିତ । ^[୭]

୧୯୫୯ରେ ସାଇପ୍ରୋହେପ୍ଟାଡାଇନ ପେଟେଣ୍ଟ୍ ହୋଇଥିଲା ଏବଂ ୧୯୬୧ରେ ଚିକିତ୍ସା ବ୍ୟବହାରରେ ଆସିଥିଲା । ^[୧୦] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ । ^[୧୧] ଯୁକ୍ତରାଜ୍ୟରେ ୪ ମିଗ୍ରାର ୩୦ଟି ଟାବଲେଟକୁ ୨୦୨୦ରେ ପ୍ରାୟ ୬ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିଥାଏ | ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶି ପ୍ରାୟ ୧୦ ଡଲାର ସାଥିରେ ସମାନ । ^[୧୨]

ଆଧାର

↑ "Cyproheptadine". Dictionary.com Unabridged. Random House.
↑ ^୨.୦ ^୨.୧ "CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]" (PDF). DailyMed. Boscogen, Inc. November 2010. Archived from the original on 4 July 2013. Retrieved 26 October 2013.
↑ ^୩.୦ ^୩.୧ "PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)" (PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011. Archived from the original (PDF) on 29 October 2013. Retrieved 26 October 2013.
↑ Gunja N, Collins M, Graudins A (2004). "A comparison of the pharmacokinetics of oral and sublingual cyproheptadine". Journal of Toxicology. Clinical Toxicology. 42 (1): 79–83. doi:10.1081/clt-120028749. PMID 15083941. S2CID 20196551.
↑ ^୫.୦ ^୫.୧ "Cyproheptadine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 December 2018. Retrieved 19 November 2020.
↑ ^୬.୦ ^୬.୧ ^୬.୨ BNF 79. London: Pharmaceutical Press. March 2020. p. 292. ISBN 978-0857113658.
↑ ^୭.୦ ^୭.୧ BNF 79. London: Pharmaceutical Press. March 2020. p. 292. ISBN 978-0857113658.
↑ "Cyproheptadine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 December 2018. Retrieved 19 November 2020.
↑ "Cyproheptadine (Periactin) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 19 November 2020.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 547. ISBN 9783527607495. Archived from the original on 2021-08-29. Retrieved 2020-09-19.
↑ "Cyproheptadine". Archived from the original on 11 November 2016. Retrieved 19 November 2020.
↑ "Cyproheptadine". Archived from the original on 11 November 2016. Retrieved 19 November 2020.

[1] "Cyproheptadine". Dictionary.com Unabridged. Random House.

[autogen1-2] ୨.୦ ^୨.୧ "CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]" (PDF). DailyMed. Boscogen, Inc. November 2010. Archived from the original on 4 July 2013. Retrieved 26 October 2013.

[autogen2-3] ୩.୦ ^୩.୧ "PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)" (PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011. Archived from the original (PDF) on 29 October 2013. Retrieved 26 October 2013.

[pmid15083941-4] Gunja N, Collins M, Graudins A (2004). "A comparison of the pharmacokinetics of oral and sublingual cyproheptadine". Journal of Toxicology. Clinical Toxicology. 42 (1): 79–83. doi:10.1081/clt-120028749. PMID 15083941. S2CID 20196551.

[AHFS2020-5] ୫.୦ ^୫.୧ "Cyproheptadine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 December 2018. Retrieved 19 November 2020.

[BNF79-6] ୬.୦ ^୬.୧ ^୬.୨ BNF 79. London: Pharmaceutical Press. March 2020. p. 292. ISBN 978-0857113658.

[autogen3-7] ୭.୦ ^୭.୧ BNF 79. London: Pharmaceutical Press. March 2020. p. 292. ISBN 978-0857113658.

[autogen5-8] "Cyproheptadine Hydrochloride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 December 2018. Retrieved 19 November 2020.

[Preg2020-9] "Cyproheptadine (Periactin) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 25 November 2020. Retrieved 19 November 2020.

[Fis2006-10] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 547. ISBN 9783527607495. Archived from the original on 2021-08-29. Retrieved 2020-09-19.

[GX2020-11] "Cyproheptadine". Archived from the original on 11 November 2016. Retrieved 19 November 2020.

[autogen7-12] "Cyproheptadine". Archived from the original on 11 November 2016. Retrieved 19 November 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]